Pancreatic Intraductal Papillary Mucinous Neoplasms: Current Diagnosis and Management

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2022 Jan 24

PMID 35070031

Authors

Beata Jablonska

Pawel Szmigiel

Slawomir Mrowiec

Affiliations

Soon will be listed here.

Abstract

Intraductal papillary mucinous neoplasms (IPMNs) represent approximately 1% of all pancreatic neoplasms and 25% of cystic neoplasms. They are divided into three types: main duct-IPMN (MD-IPPMN), branch duct-IPMN (BD-IPMN), and mixed type-IPMN. In this review, diagnostics, including clinical presentation and radiological investigations, were described. Magnetic resonance imaging is the most useful for most IPMNs. Management depends on the type and radiological features of IPMNs. Surgery is recommended for MD-IPMN. For BD-IPMN, management involves surgery or surveillance depending on the tumor size, cyst growth rate, solid components, main duct dilatation, high-grade dysplasia in cytology, the presence of symptoms (jaundice, new-onset diabetes, pancreatitis), and CA 19.9 serum level. The patient's age and comorbidities should also be taken into consideration. Currently, there are different guidelines regarding the diagnosis and management of IPMNs. In this review, the following guidelines were presented: Sendai International Association of Pancreatology guidelines (2006), American Gastroenterological Association guidelines, revised international consensus Fukuoka guidelines (2012), revised international consensus Fukuoka guidelines (2017), and European evidence-based guidelines according to the European Study Group on Cystic Tumours of the Pancreas (2018). The Verona Evidence-Based Meeting 2020 was also presented and discussed.

Citing Articles

GI cancer mortality in participants in low dose CT screening for lung cancer with a focus on pancreatic cancer.

Gros L, Yip R, Zhu Y, Li P, Paksashvili N, Sun Q Sci Rep. 2024; 14(1):29851.

PMID: 39617764 PMC: 11609297. DOI: 10.1038/s41598-024-76322-z.

An Overview for Clinicians on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas.

Moris D, Liapis I, Gupta P, Ziogas I, Karachaliou G, Dimitrokallis N Cancers (Basel). 2024; 16(22).

PMID: 39594780 PMC: 11593033. DOI: 10.3390/cancers16223825.

An Autopsy Case of Myotonic Dystrophy Type 1 With Pancreatic Intraductal Papillary Mucinous Neoplasm.

Nonaka K, Arakawa A, Hara M, Komatsu A, Nagasaka T, Kumasaka T Cureus. 2024; 16(9):e70225.

PMID: 39463607 PMC: 11512164. DOI: 10.7759/cureus.70225.

A Unique Presentation of Diffuse Intraductal Papillary Mucinous Neoplasm of Bile Duct Successfully Treated With Orthotopic Liver Transplant and Pancreaticoduodenectomy Procedure: A Case Report.

Fang Y, OLeary C, Lowe H, Carpenter D, Randall H, Nazzal M Cureus. 2024; 16(9):e70177.

PMID: 39463545 PMC: 11506687. DOI: 10.7759/cureus.70177.

Challenges of Managing Type 3c Diabetes in the Context of Pancreatic Resection, Cancer and Trauma.

Wayne C, Benbetka C, Besner G, Narayanan S J Clin Med. 2024; 13(10).

PMID: 38792534 PMC: 11122338. DOI: 10.3390/jcm13102993.

References

Jang J, Kim M, Jeong S, Kim J, Park D, Lee S . Clinical characteristics of intraductal papillary mucinous neoplasm manifesting as acute pancreatitis or acute recurrent pancreatitis. J Gastroenterol Hepatol. 2013; 28(4):731-8. DOI: 10.1111/jgh.12121. View

Murayama S, Kimura W, Hirai I, Takasu N, Takeshita A, Moriya T . Volumetric and morphological analysis of intraductal papillary mucinous neoplasm of the pancreas using computed tomography and magnetic resonance imaging. Pancreas. 2011; 40(6):876-82. DOI: 10.1097/MPA.0b013e31821fdcff. View

Vege S, Ziring B, Jain R, Moayyedi P . American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015; 148(4):819-22. DOI: 10.1053/j.gastro.2015.01.015. View

Crippa S, Arcidiacono P, De Cobelli F, Falconi M . Review of the diagnosis and management of intraductal papillary mucinous neoplasms. United European Gastroenterol J. 2020; 8(3):249-255. PMC: 7184662. DOI: 10.1177/2050640619894767. View

Hsiao C, Yang C, Wu J, Kuo T, Tien Y . Utility of the 2006 Sendai and 2012 Fukuoka guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas: A single-center experience with 138 surgically treated patients. Medicine (Baltimore). 2016; 95(38):e4922. PMC: 5044913. DOI: 10.1097/MD.0000000000004922. View

Adsay N, Merati K, Andea A, Sarkar F, Hruban R, Wilentz R . The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002; 15(10):1087-95. DOI: 10.1097/01.MP.0000028647.98725.8B. View

Tanaka M . International consensus on the management of intraductal papillary mucinous neoplasm of the pancreas. Ann Transl Med. 2015; 3(19):286. PMC: 4671873. DOI: 10.3978/j.issn.2305-5839.2015.11.09. View

Boraschi P, Tarantini G, Donati F, Scalise P, Cervelli R, Caramella D . Side-branch intraductal papillary mucinous neoplasms of the pancreas: outcome of MR imaging surveillance over a 10 years follow-up. Eur J Radiol Open. 2020; 7:100250. PMC: 7452648. DOI: 10.1016/j.ejro.2020.100250. View

Perez-Cuadrado-Robles E, Uribarri-Gonzalez L, Borbath I, Vila J, Lopez-Lopez S, Deprez P . Risk of advanced lesions in patients with branch-duct IPMN and relative indications for surgery according to European evidence-based guidelines. Dig Liver Dis. 2018; 51(6):882-886. DOI: 10.1016/j.dld.2018.11.028. View

10.

Yamashita Y, Joshita S, Ito T, Maruyama M, Wada S, Umemura T . A case report of pancreatic panniculitis due to acute pancreatitis with intraductal papillary mucinous neoplasm. BMC Gastroenterol. 2020; 20(1):286. PMC: 7445916. DOI: 10.1186/s12876-020-01430-9. View

11.

Takeshita K, Kutomi K, Takada K, Haruyama T, Fukushima J, Aida R . Differential diagnosis of benign or malignant intraductal papillary mucinous neoplasm of the pancreas by multidetector row helical computed tomography: evaluation of predictive factors by logistic regression analysis. J Comput Assist Tomogr. 2008; 32(2):191-7. DOI: 10.1097/RCT.0b013e3180676d97. View

12.

Gahr N, Technau K, Ghanem N . Intraductal papillary mucinous adenoma of the pancreas presenting with lobular panniculitis. Eur Radiol. 2005; 16(6):1397-8. DOI: 10.1007/s00330-005-0058-4. View

13.

Kadayifci A, Atar M, Wang J, Forcione D, Casey B, Pitman M . Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms. Dig Endosc. 2016; 29(1):111-117. DOI: 10.1111/den.12710. View

14.

Tanaka M, Fernandez-Del Castillo C, Kamisawa T, Jang J, Levy P, Ohtsuka T . Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017; 17(5):738-753. DOI: 10.1016/j.pan.2017.07.007. View

15.

Venkatesh P, Navaneethan U, Vege S . Intraductal papillary mucinous neoplasm and acute pancreatitis. J Clin Gastroenterol. 2011; 45(9):755-8. DOI: 10.1097/MCG.0b013e31821b1081. View

16.

Marchegiani G, Salvia R . Guidelines on Pancreatic Cystic Neoplasms: Major Inconsistencies With Available Evidence and Clinical Practice- Results From an International Survey. Gastroenterology. 2021; 160(7):2234-2238. DOI: 10.1053/j.gastro.2021.02.026. View

17.

Bernardoni L, Crino S, De Conti G, Conti Bellocchi M, de Pretis N, Amodio A . Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis. Endosc Int Open. 2017; 5(11):E1144-E1150. PMC: 5677465. DOI: 10.1055/s-0043-119753. View

18.

Qian D, Shen B, Zhan X, Peng C, Cheng D . Liquefying panniculitis associated with intraductal papillary mucinous neoplasm. JRSM Short Rep. 2011; 2(5):38. PMC: 3105454. DOI: 10.1258/shorts.2011.010141. View

19.

Srinivasan N, Teo J, Chin Y, Hennedige T, Tan D, Low A . Systematic review of the clinical utility and validity of the Sendai and Fukuoka Consensus Guidelines for the management of intraductal papillary mucinous neoplasms of the pancreas. HPB (Oxford). 2018; 20(6):497-504. DOI: 10.1016/j.hpb.2018.01.009. View

20.

Castellano-Megias V, Ibarrola-de Andres C, Lopez-Alonso G, Colina-Ruizdelgado F . Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas. World J Gastrointest Oncol. 2014; 6(9):311-24. PMC: 4163729. DOI: 10.4251/wjgo.v6.i9.311. View